Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan plus HTK cardioplegia versus HTK cardioplegia alone in poor cardiac function undergoing CABG
PACTR202207785952318Phase 4Not yet recruiting
- Sponsor
- Maha Elkotb
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan in coronary arteriosclerosis and heart failure (HF) (2 arms), sponsored by Maha Elkotb. Primary endpoint: Vasoactive inotropic score. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
levosimendan
03
Conditions
coronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on PACTR202207785952318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202207785952318.